Investing.com | Editor Emilio Ghigini
Published Apr 08, 2024 07:43AM ET
CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical company, today announced positive results from its Phase 3 clinical trial for PL9643, a potential treatment for dry eye disease (DED). The study's findings were presented at the American Society of Cataract and Refractive Surgery (ASCRS) conference in Boston.
The trial, named MELODY-1, demonstrated that the treatment with PL9643 led to statistically significant improvements in the primary symptom endpoint of pain and several secondary endpoints over a 12-week period compared to a placebo. The study also highlighted the treatment's rapid onset of efficacy, with significant results observed as early as two weeks into the treatment.
Dr. Eric Donnenfeld's presentation at the ASCRS conference on Friday outlined the trial's success and emphasized PL9643's favorable safety and tolerability profile. The treatment was well-received, with fewer ocular treatment-related adverse events and study discontinuations in the PL9643 arm compared to the placebo.
The MELODY-1 trial was a multi-center, randomized, double-masked, and vehicle-controlled study that enrolled 575 patients across the U.S. It was designed based on encouraging Phase 2 results and discussions with the FDA regarding pivotal Phase 3 clinical program elements.
Palatin's CEO, Carl Spana, Ph.D., expressed confidence in PL9643's broad and robust efficacy for multiple symptom endpoints. The company plans to engage with the FDA in the second quarter of 2024 to discuss the remaining studies needed to support a New Drug Application (NDA) submission.
This news comes at a time when the dry eye disease market is substantial and growing, with an estimated 38 million people affected in the U.S. alone. The market is projected to reach $7.46 billion by 2029, growing at a CAGR of 4.09% from 2024.
Palatin aims to address the significant unmet medical needs for an effective DED treatment and is actively preparing for potential collaborations and regulatory discussions. The information is based on a press release statement from Palatin Technologies.
h2 InvestingPro Insights/h2As Palatin Technologies, Inc. (NYSE American: PTN) announces promising clinical trial results for its dry eye disease treatment, PL9643, it's crucial for investors to consider the company's financial health and market performance. InvestingPro provides a snapshot of the company's current financial metrics and analyst expectations that could influence investment decisions.
InvestingPro Data:
InvestingPro Tips:
These financial insights suggest that while Palatin Technologies is making strides in clinical development, the company faces financial challenges, including profitability and cash flow concerns. For investors interested in a deeper analysis, there are an additional 9 InvestingPro Tips available at https://www.investing.com/pro/PTN, which could provide further guidance on the company's prospects.
To access these insights and more, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.